Consequently, this retrospective study has two objectives: (1) to compare the clinical characteristics and prognosis of EGFR‐mutated NSCLC patients with and without initial BoM; and (2) to identify effective hybrid treatment strategies. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.